Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational study
Higher ADA concentrations and lower drug clearance are associated with better clinical outcomes in HS. ROC analysis identified 10.7 μg/mL (ADA concentration) and 0.5 L/day (clearance) as optimal cut-off values to differentiate low from partial/high responders. These findings suggest that therapeutic drug monitoring may help optimize ADA therapy in HS.
Authors
- Martina Letko Porter
- Prerna Salian
- C. Snyder (ORCID: https://orcid.org/0000-0002-6917-5277)
- T. Otto (ORCID: https://orcid.org/0000-0002-6385-0470)
- Stella Chen (ORCID: https://orcid.org/0000-0002-3453-4786)
- Sydney Look-Why
- Alexa B. Kimball (ORCID: https://orcid.org/0000-0001-9405-0479)
- Maneli Doroudian Tehrani
- Thierry Dervieux (ORCID: https://orcid.org/0000-0002-3799-4438)
- Nazrin Ashina
- William Sweet
- Bruna Galvao de O. Wafae
- Ruby Gibson
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Prometheus (United States) (US)
- Deaconess Hospital (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fimmu.2026.1760206
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beth Israel Deaconess Medical Center